ArticleAmerican journal of respiratory and critical care medicine2020
A Human Lung Challenge Model to Evaluate the Safety and Immunogenicity of PPD and Live Bacillus Calmette-Guérin.
Abstract read
In one paragraph
Article in American journal of respiratory and critical care medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 49 citations in OpenAlex.
- Early mucosal responses following a randomised controlled human inhaled infection with attenuated Mycobacterium bovis BCG.Nature communications · 2025Trial
- Probing Dermal Immunity to Mycobacteria through a Controlled Human Infection Model.ImmunoHorizons · 2024Trial
- Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial.The Lancet. Infectious diseases · 2024Trial
- Lung mucosal and systemic responses at single-cell resolution in an aerosolized Mycobacterium bovis BCG human challenge model.Cell reports. Medicine · 2026Article
- Influenza coinfection inhibits control of mycobacterial infection in a human challenge model.Nature communications · 2026Article
- BCG immunisation through intranasal instillation protects mice against Streptococcus pneumoniae infection by enhancing alveolar macrophage activity.Scientific reports · 2026Article
- Exploring the ethics of tuberculosis human challenge models.Journal of medical ethics · 2026Article
- Controlled human infection with Mycobacterium tuberculosis: practical considerations for clinical trials.The Lancet. Microbe · 2026Review
- Acceptability of advanced Controlled Human Infection Models: The case of a pneumococcal challenge in people living with HIV and mycobacterial challenge with Bacillus Calmette Guerin in Malawi.PLOS global public health · 2026Article
- Engineering mycobacteria for vaccination and controlled human infection studies.Nature microbiology · 2025Article
- Article
- Engineered Mycobacterium tuberculosis triple-kill-switch strain provides controlled tuberculosis infection in animal models.Nature microbiology · 2025Article
- Challenges in developing new tuberculosis vaccines.Memorias do Instituto Oswaldo Cruz · 2025Review
- Symptoms and adverse events in controlled human infection models.Frontiers in medicine · 2025Review
- Driving innovation from discovery to access: Meeting report of the 7Gates open research · 2025Article
- Immune correlates of protection as a game changer in tuberculosis vaccine development.NPJ vaccines · 2024Review
- Review of Current Tuberculosis Human Infection Studies for Use in Accelerating Tuberculosis Vaccine Development: A Meeting Report.The Journal of infectious diseases · 2024Article
- A noninvasive BCG skin challenge model for assessing tuberculosis vaccine efficacy.PLoS biology · 2024Article
- Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus Calmette-Guérin Challenge Model for Assessment of Tuberculosis Immunity In Vivo.The Journal of infectious diseases · 2024Article
- Antigen identification strategies and preclinical evaluation models for advancing tuberculosis vaccine development.NPJ vaccines · 2024Review
Corrections and comments
- Commented on by
Authors and funding
18 authors at 2 institutions in 2 countries.
Malika DavidsCentre for Lung Infection and Immunity, University of Cape Town Lung Institute, Cape Town, South Africa.
Anil PooranCentre for Lung Infection and Immunity, University of Cape Town Lung Institute, Cape Town, South Africa.
Clemens HermannDepartment of Integrative Biomedical Sciences, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Lynelle MottayCentre for Lung Infection and Immunity, University of Cape Town Lung Institute, Cape Town, South Africa.
Fawziyah ThompsonCentre for Lung Infection and Immunity, University of Cape Town Lung Institute, Cape Town, South Africa.
Jacob CardenasBaylor Institute for Immunology Research, Dallas, Texas; and.
Jinghua GuBaylor Institute for Immunology Research, Dallas, Texas; and.
Thearith KoeuthBaylor Institute for Immunology Research, Dallas, Texas; and.
Richard MeldauCentre for Lung Infection and Immunity, University of Cape Town Lung Institute, Cape Town, South Africa.
Jason LimberisCentre for Lung Infection and Immunity, University of Cape Town Lung Institute, Cape Town, South Africa.
Phindile GinaCentre for Lung Infection and Immunity, University of Cape Town Lung Institute, Cape Town, South Africa.
Shashikant SrivastavaBaylor Institute for Immunology Research, Dallas, Texas; and.
Bridget CalderDepartment of Integrative Biomedical Sciences, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Aliasgar EsmailCentre for Lung Infection and Immunity, University of Cape Town Lung Institute, Cape Town, South Africa.
Michele TomasicchioCentre for Lung Infection and Immunity, University of Cape Town Lung Institute, Cape Town, South Africa.
Jonathan BlackburnDepartment of Integrative Biomedical Sciences, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Tawanda GumboBaylor Institute for Immunology Research, Dallas, Texas; and.
Keertan DhedaCentre for Lung Infection and Immunity, University of Cape Town Lung Institute, Cape Town, South Africa.ORCID 0000-0001-7709-5341
South African Medical Research Council · ZAUniversity of Cape Town · ZA
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
BronchoscopyImmunogenicity, VaccineAdjuvants, ImmunologicAdministration, TopicalAdultBCG VaccineFeasibility StudiesFemaleHumansImmunity, MucosalMaleTuberculinTuberculosisYoung AdultAdjuvants, ImmunologicBCG VaccineTuberculinBCGimmunologytuberculosisvaccine
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.